Literature DB >> 22015106

Differences in the concentration and correlation of cervical immune markers among HPV positive and negative perimenopausal women.

Morgan A Marks1, Raphael P Viscidi, Kathryn Chang, Michelle Silver, Anne Burke, Roslyn Howard, Patti E Gravitt.   

Abstract

INTRODUCTION: Women≥45years of age with persistent HPV infections have distinct peripheral circulating immune profiles. Few studies have comprehensively evaluated the cervical immunologic microenvironment in HPV-positive and HPV-negative perimenopausal women.
METHODS: We collected cervical secretion specimens from 34 high risk HPV (HR-HPV) positive and 44 HR-HPV negative women enrolled in an ongoing prospective cohort assessing the natural history of HPV across the menopausal transition. We used these specimens to quantify concentrations of 27 different immune markers using multiplexed bead-based immunoassays.
RESULTS: HR-HPV positive women had significantly higher median concentrations of IL-5 (0.11 ng/mgtotal protein vs. 0.08 ng/mgtotal protein), IL-9 (2.7 ng/mgtotal protein vs. 2.1 ng/mgtotal protein), IL-13 (2.1 ng/mgtotal protein vs. 0.9 ng/mgtotal protein), IL-17 (2.9 ng/mgtotal protein vs. 1.1 ng/mgtotal protein), EOTAXIN (4.1 ng/mgtotal protein vs. 1.1 ng/mgtotal protein), GM-CSF (4.3 ng/mgtotal protein vs. 3.3 ng/mgtotal protein), and MIP-1α (3.5 ng/mgtotal protein vs. 1.9 ng/mgtotal protein) compared to HR-HPV negative women. A shift in the correlation of T-cell and pro-inflammatory cytokines (IFN-γ, IL-5, IL-9, IL-10, IL-12, IL-13, IL-15, and TNF-α) from IL-2 to EOTAXIN was observed between HR-HPV negative and positive women.
CONCLUSIONS: Higher local concentrations of anti-inflammatory and allergy associated markers, with a shift in T-cell associated cytokine correlation from IL-2 to EOTAXIN, are associated with HPV infection among older women.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22015106      PMCID: PMC3831521          DOI: 10.1016/j.cyto.2011.09.012

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


  27 in total

1.  Improved amplification of genital human papillomaviruses.

Authors:  P E Gravitt; C L Peyton; T Q Alessi; C M Wheeler; F Coutlée; A Hildesheim; M H Schiffman; D R Scott; R J Apple
Journal:  J Clin Microbiol       Date:  2000-01       Impact factor: 5.948

Review 2.  Assessment of mucosal immunity to HIV-1.

Authors:  Vicky Jespers; Ali M Harandi; Jorma Hinkula; Donata Medaglini; Roger Le Grand; Christiane Stahl-Hennig; Willy Bogers; Raphaelle El Habib; Frank Wegmann; Carol Fraser; Martin Cranage; Robin J Shattock; Anna-Lena Spetz
Journal:  Expert Rev Vaccines       Date:  2010-04       Impact factor: 5.217

3.  Use of PGMY primers in L1 consensus PCR improves detection of human papillomavirus DNA in genital samples.

Authors:  François Coutlée; Patti Gravitt; Janet Kornegay; Catherine Hankins; Harriet Richardson; Normand Lapointe; Hélène Voyer; Eduardo Franco
Journal:  J Clin Microbiol       Date:  2002-03       Impact factor: 5.948

4.  Local applications of GM-CSF induce the recruitment of immune cells in cervical low-grade squamous intraepithelial lesions.

Authors:  Pascale Hubert; Jean Doyen; Xavier Capelle; Mohammad Arafa; Virginie Renoux; Bettina Bisig; Laurence Seidel; Brigitte Evrard; Latifa Bousarghin; Colette Gerday; Jacques Boniver; Jean-Michel Foidart; Philippe Delvenne; Nathalie Jacobs
Journal:  Am J Reprod Immunol       Date:  2010-03-29       Impact factor: 3.886

Review 5.  Immune responses to human papillomavirus.

Authors:  Margaret Stanley
Journal:  Vaccine       Date:  2006-03-30       Impact factor: 3.641

Review 6.  Chemokines in asthma: cooperative interaction between chemokines and IL-13.

Authors:  Nives Zimmermann; Gurjit Khurana Hershey; Paul S Foster; Marc E Rothenberg
Journal:  J Allergy Clin Immunol       Date:  2003-02       Impact factor: 10.793

Review 7.  Th9 and allergic disease.

Authors:  Pejman Soroosh; Taylor A Doherty
Journal:  Immunology       Date:  2009-08       Impact factor: 7.397

Review 8.  GM-CSF in inflammation and autoimmunity.

Authors:  John A Hamilton
Journal:  Trends Immunol       Date:  2002-08       Impact factor: 16.687

9.  Specific antibody levels at the cervix during the menstrual cycle of women vaccinated with human papillomavirus 16 virus-like particles.

Authors:  Denise Nardelli-Haefliger; Daniel Wirthner; John T Schiller; Douglas R Lowy; Allan Hildesheim; Françoise Ponci; Pierre De Grandi
Journal:  J Natl Cancer Inst       Date:  2003-08-06       Impact factor: 13.506

Review 10.  Methodological issues in sampling the local immune system of the female genital tract in the context of HIV prevention trials.

Authors:  Vicky Jespers; Suzanna C Francis; Janneke van de Wijgert; Tania Crucitti
Journal:  Am J Reprod Immunol       Date:  2010-12-27       Impact factor: 3.886

View more
  23 in total

1.  IL-17 suppresses immune effector functions in human papillomavirus-associated epithelial hyperplasia.

Authors:  Christina Gosmann; Stephen R Mattarollo; Jennifer A Bridge; Ian H Frazer; Antje Blumenthal
Journal:  J Immunol       Date:  2014-07-25       Impact factor: 5.422

2.  Cervical cytokines and clearance of incident human papillomavirus infection: Hawaii HPV cohort study.

Authors:  Mark E Scott; Yurii B Shvetsov; Pamela J Thompson; Brenda Y Hernandez; Xuemei Zhu; Lynne R Wilkens; Jeffrey Killeen; Dien D Vo; Anna-Barbara Moscicki; Marc T Goodman
Journal:  Int J Cancer       Date:  2013-03-16       Impact factor: 7.396

3.  Oral sampling methods are associated with differences in immune marker concentrations.

Authors:  Carole Fakhry; Fares Qeadan; Robert H Gilman; Pablo Yori; Margaret Kosek; Nicole Patterson; David W Eisele; Christine G Gourin; Chandala Chitguppi; Morgan Marks; Patti Gravitt
Journal:  Laryngoscope       Date:  2017-11-24       Impact factor: 3.325

4.  Evaluation of a multiplex panel of immune-related markers in cervical secretions: a methodologic study.

Authors:  Jill Koshiol; Martha Sklavos; Nicolas Wentzensen; Troy Kemp; Mark Schiffman; S Terence Dunn; Sophia S Wang; Joan L Walker; Mahboobeh Safaeian; Rosemary E Zuna; Allan Hildesheim; Ruth M Pfeiffer; Ligia A Pinto
Journal:  Int J Cancer       Date:  2013-07-30       Impact factor: 7.396

5.  Contributions of recent and past sexual partnerships on incident human papillomavirus detection: acquisition and reactivation in older women.

Authors:  Anne F Rositch; Anne E Burke; Raphael P Viscidi; Michelle I Silver; Kathryn Chang; Patti E Gravitt
Journal:  Cancer Res       Date:  2012-09-27       Impact factor: 12.701

6.  Comparison of normalization methods for measuring immune markers in cervical secretion specimens.

Authors:  Morgan A Marks; Yolanda Eby; Roslyn Howard; Patti E Gravitt
Journal:  J Immunol Methods       Date:  2012-06-04       Impact factor: 2.303

7.  A cohort effect of the sexual revolution may be masking an increase in human papillomavirus detection at menopause in the United States.

Authors:  Patti E Gravitt; Anne F Rositch; Michelle I Silver; Morgan A Marks; Kathryn Chang; Anne E Burke; Raphael P Viscidi
Journal:  J Infect Dis       Date:  2012-12-12       Impact factor: 5.226

8.  The correlation between human papillomavirus positivity and abnormal cervical cytology result differs by age among perimenopausal women.

Authors:  Anne F Rositch; Michelle I Silver; Anne Burke; Raphael Viscidi; Kathryn Chang; Cindy M P Duke; Wen Shen; Patti E Gravitt
Journal:  J Low Genit Tract Dis       Date:  2013-01       Impact factor: 1.925

9.  Severe cervical inflammation and high-grade squamous intraepithelial lesions: a cross-sectional study.

Authors:  Tengfei Long; Lingli Long; Yaxiao Chen; Yubin Li; Ying Tuo; Yue Hu; Lingling Xie; Gui He; Wen Zhao; Xiaofang Lu; Zhongqiu Lin
Journal:  Arch Gynecol Obstet       Date:  2020-09-26       Impact factor: 2.344

10.  Obesity and human papillomavirus infection in perimenopausal women.

Authors:  Su-Hsun Liu; Anne F Rositch; Raphael P Viscidi; Michelle I Silver; Anne E Burke; Patti E Gravitt
Journal:  J Infect Dis       Date:  2013-07-09       Impact factor: 5.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.